Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
8 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CDS SABOURAUD
PAVILLON BIET 2 PL DR ALFRED FOURNIER, 75010 PARIS
CABINET DU DR JOSIANE PARIER
3 AVENUE CHANZY, 94210 LA VARENNE ST HILAIRE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Acta dermato-venereologica · 2020
Acta dermato-venereologica · 2025
Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce. This prospective, observational, multicentric study aimed to assess the long-term effectiveness and safety of tralokinumab in patients with AD in a real-world setting. Primary outcomes included 50%, 75%, and 90% improvement in Eczema Area and Severity Index score (EASI50, EASI75, EASI90, respectively) and improvements in Dermatology Life Quality Index (DLQI) at 1 year. A total of 136 patients with AD were enrolled in the study; data at 1-year follow-up were available for 111 patients. After 1 year, 68.5% and 33.3% of patients achieved an EASI75 and EASI90, respectively. A significantly higher percentage of patients with than without foot involvement achieved EASI50 (p = 0.009) and EASI75 (p = 0.022). Similarly, hand involvement was significantly associated with higher EASI50 response (p = 0.005). Median DLQI score decreased from 9.00 (interquartile range (IQR): 6.00, 13.75) to 1.00 (IQR: 0.00, 4.00) after 1 year of treatment. Adverse events included blepharitis (n = 10), conjunctivitis (n = 6), and injection-site reactions (n = 2). Tralokinumab can be an effective and safe treatment for patients with moderate-to-severe AD. Involvement of certain body areas, such as hands and feet, might positively predict a clinical response to tralokinumab.
Acta dermato-venereologica · 2023
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Acta dermato-venereologica · 2025 · Journal Article
Calabrese L, Cinotti E, D'Onghia M, Cartocci A, et al.
Acta dermato-venereologica · 2020 · Journal Article
Phan C, Beneton N, Delaunay J, Reguiai Z, et al.
Drugs & aging · 2020 · Journal Article
Phan C, Beneton N, Delaunay J, Reguiai Z, et al.
Acta dermato-venereologica · 2025 · Journal Article
Calabrese L, Cinotti E, D'Onghia M, Cartocci A, et al.
Acta dermato-venereologica · 2020 · Journal Article
Phan C, Beneton N, Delaunay J, Reguiai Z, et al.
Acta dermato-venereologica · 2025 · Journal Article
Mathieu C, Maccari F, Perrot JL, Reguiai Z, et al.
Acta dermato-venereologica · 2020 · Journal Article
Phan C, Beneton N, Delaunay J, Reguiai Z, et al.
Clinical, cosmetic and investigational dermatology · 2021 · Journal Article
Fougerousse AC, Mery-Bossard L, Parier J, Taieb C, et al.
Dermatology (Basel, Switzerland) · 2024 · Journal Article
Becherel PA, Reguiai Z, Fougerousse AC, Perrot JL, et al.
Dermatology (Basel, Switzerland) · 2022 · Journal Article
Jendoubi F, Balica S, Richard MA, Chiaverini C, et al.
Acta dermato-venereologica · 2023 · Journal Article
Reguiai Z, Becherel PA, Perrot JL, Fougerousse AC, et al.
Dermatology (Basel, Switzerland) · 2022 · Journal Article
Jendoubi F, Balica S, Richard MA, Chiaverini C, et al.
Drugs & aging · 2020 · Journal Article
Phan C, Beneton N, Delaunay J, Reguiai Z, et al.